Tags

Type your tag names separated by a space and hit enter

Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
Hum Reprod. 2005 Jan; 20(1):175-9.HR

Abstract

BACKGROUND

The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).

METHODS

Thirty clomiphene citrate-resistant patients were selected randomly and divided into two groups. Group I was treated with 100 mg/day clomiphene citrate and 300 mg/day acarbose 100 mg/day orally, for 3 months. Group II was treated with clomiphene citrate 100 mg/day and metformin 1700 mg/day orally, for 3 months. Serum fasting insulin and glucose, FSH, LH, estradiol, progesterone, prolactin and total testosterone levels plus body mass index (BMI) were measured before and after treatment. Follicle growth was followed by transvaginal ultrasonography.

RESULTS

LH:FSH ratio and total testosterone concentrations decreased (P<0.05) and ovulation rates increased in both groups. Reduction in weight and BMI was only significant in the acarbose group.

CONCLUSIONS

Both treatment modalities were effective in the treatment of insulin resistance and improving ovulation rates. Increase in the number of eumenorrhoeic and normoinsulinaemic cases and decrease in the number of insulin-resistant cases were significant in both groups (P<0.05). Ovulation rate was greater in the metformin group in the second month of therapy (P<0.05). Acarbose was found to be a safe and effective agent that could be used in cases with clomiphene-resistant PCOS.

Authors+Show Affiliations

Sönmez AS
Süleymaniye Maternity and Women's Disease Research and Teaching Hospital, Assisted Reproductive Techniques Unit and Istanbul University, Istanbul, Turkey. suhas@net.net.tr
Yasar L
No affiliation info available
Savan K
No affiliation info available
Koç S
No affiliation info available
Ozcan J
No affiliation info available
Toklar A
No affiliation info available
Yazicioğu F
No affiliation info available
Akgün A
No affiliation info available
Sut N
No affiliation info available

MeSH

AcarboseAdultBlood GlucoseClomipheneDrug ResistanceFemaleFollicle Stimulating HormoneHumansHypoglycemic AgentsInsulinInsulin ResistanceLuteinizing HormoneMetforminOvulationOvulation InductionPolycystic Ovary SyndromeTestosterone

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15513975

Citation

Sönmez, A S., et al. "Comparison of the Effects of Acarbose and Metformin Use On Ovulation Rates in Clomiphene Citrate-resistant Polycystic Ovary Syndrome." Human Reproduction (Oxford, England), vol. 20, no. 1, 2005, pp. 175-9.
Sönmez AS, Yasar L, Savan K, et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod. 2005;20(1):175-9.
Sönmez, A. S., Yasar, L., Savan, K., Koç, S., Ozcan, J., Toklar, A., Yazicioğu, F., Akgün, A., & Sut, N. (2005). Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Human Reproduction (Oxford, England), 20(1), 175-9.
Sönmez AS, et al. Comparison of the Effects of Acarbose and Metformin Use On Ovulation Rates in Clomiphene Citrate-resistant Polycystic Ovary Syndrome. Hum Reprod. 2005;20(1):175-9. PubMed PMID: 15513975.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. AU - Sönmez,A S, AU - Yasar,L, AU - Savan,K, AU - Koç,S, AU - Ozcan,J, AU - Toklar,A, AU - Yazicioğu,F, AU - Akgün,A, AU - Sut,N, Y1 - 2004/10/28/ PY - 2004/10/30/pubmed PY - 2005/6/14/medline PY - 2004/10/30/entrez SP - 175 EP - 9 JF - Human reproduction (Oxford, England) JO - Hum Reprod VL - 20 IS - 1 N2 - BACKGROUND: The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS). METHODS: Thirty clomiphene citrate-resistant patients were selected randomly and divided into two groups. Group I was treated with 100 mg/day clomiphene citrate and 300 mg/day acarbose 100 mg/day orally, for 3 months. Group II was treated with clomiphene citrate 100 mg/day and metformin 1700 mg/day orally, for 3 months. Serum fasting insulin and glucose, FSH, LH, estradiol, progesterone, prolactin and total testosterone levels plus body mass index (BMI) were measured before and after treatment. Follicle growth was followed by transvaginal ultrasonography. RESULTS: LH:FSH ratio and total testosterone concentrations decreased (P<0.05) and ovulation rates increased in both groups. Reduction in weight and BMI was only significant in the acarbose group. CONCLUSIONS: Both treatment modalities were effective in the treatment of insulin resistance and improving ovulation rates. Increase in the number of eumenorrhoeic and normoinsulinaemic cases and decrease in the number of insulin-resistant cases were significant in both groups (P<0.05). Ovulation rate was greater in the metformin group in the second month of therapy (P<0.05). Acarbose was found to be a safe and effective agent that could be used in cases with clomiphene-resistant PCOS. SN - 0268-1161 UR - https://www.unboundmedicine.com/medline/citation/15513975/Comparison_of_the_effects_of_acarbose_and_metformin_use_on_ovulation_rates_in_clomiphene_citrate_resistant_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -